Credit: Canva
Fasting may reset your body, but can it reset your mind? The new trend of dopamine fasting claims it can. And wait, there's more. This trend also works against dopamine resistance, implying that things that did not make you happier before will now do. You see, dopamine is a part of the brain's reward system and plays an important role in your pleasure reception. While this neurotransmitter is not directly linked to an individual's happiness, it triggers feelings of satisfaction, motivation and pleasure.
However, a person can also reach a stage of dopamine resistance if they continue to indulge in activities that trigger its frequent or constant release. In this case, the individual stops feeling the impact of this neurotransmitter and thus, does feel good or happy.
So does dopamine fasting work?
Dopamine fasting is a practice where individuals limit their exposure to activities or stimuli that typically provide a surge of dopamine. The idea behind dopamine fasting is to reset or recalibrate the brain's reward system. This is usually done by abstaining from gratifying things or experiences like social media, junk food, and even sex. Proponents of dopamine fasting argue that continual overstimulation from digital devices, social media, and easily accessible indulgences has numbed our brain's reward pathways. By regularly denying ourselves these dopamine triggers, the idea claims, we might restore our ability to acquire fulfilment from life's basic pleasures.
Having low levels of dopamine can make you less motivated and excited about things. In Parkinson's disease, there is not enough dopamine in the areas of the brain important for movement. This leads to problems with muscle stiffness and movements such as walking.
The symptoms of a dopamine imbalance depend on what is causing the problem. They include physical symptoms such as:
Adjusting dopamine levels is complicated, as it is involved in many different roles in the brain. Your doctor won't measure your dopamine levels directly, and there is no simple test to measure it. Your symptoms will be the clues that tell your doctor if you have too much or not enough dopamine. They will then prescribe medicines to adjust your dopamine level, based on your symptoms, and make adjustments based on how your body responds and how you feel.
ALSO READ: Not Just a Screen Time Fix: 5 Timeless Health Habits from the ’50s
Credit: iStock
A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.
The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.
The hexavalent vaccine protects children against six diseases with a single injection:
Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.
Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526
Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.
The study estimated that:
The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.
According to the study, introducing the hexavalent vaccine could:
Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients
India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.
The program protects children against 12 vaccine-preventable diseases, including:
A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:
The analysis considered costs from both government and household perspectives, including:
The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:
The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.
"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.
Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.
Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.
The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.
"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.
Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.
Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study
The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.
Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.
Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.
Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.
The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.
The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.
While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.
Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.
"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.
Credit: iStock
As many as 23 cases of young women aged below 35 suffering from heart-related problems in only a month (reported by the Indian Medical Association) have left cardiologists concerned. What were earlier considered symptoms of stress, anxiety, and hormonal imbalances such as chest pain, breathing difficulty, palpitations, unexplained fatigue, and giddiness are now not being taken lightly when they occur for a prolonged time or recur. They are being increasingly identified as cardiac-related problems even in young adults.
Lack of physical activity, improper diet, obesity, diabetes, high blood pressure, smoking, and continuous stress have been labeled responsible for these problems. Some women's conditions like PCOD and autoimmune diseases can also put them at a higher cardiovascular risk. Regular check-ups, monitoring of blood pressure, blood sugar, cholesterol levels, and timely check-ups for the heart whenever these conditions occur can help in detecting the problems at the earliest, thus initiating treatment and recovery effectively.
In today's times, management of complicated heart diseases in India has dramatically improved and achieved outcomes at par with global standards. Today, the management of very severe heart valve disease offers much in terms of percutaneous catheter-based solutions, which, alongside conventional surgery (performed according to a person's age, general health, and clinical profile), give improved outcomes. Early detection and management of heart diseases prevent major complications and restore an individual's quality of life.
Increased knowledge about heart health, early identification of symptoms, and immediate medical attention are very important to achieve successful results. The observance of preventive measures such as engaging in regular exercise, a healthy diet, sleep, managing stress, and conducting regular medical checkups helps in the prevention of heart problems. Early diagnosis and adequate treatment form the key factors for achieving the best heart health.
By Dr. Nagendra Singh Chouhan, Interventional Cardiologist at Medanta Hospitals, Gurugram
© 2024 Bennett, Coleman & Company Limited